MPM Oncology Impact Management »

Natera shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Natera (NTRA) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Natera

Tip: Access up to 7 years of quarterly data

All positions including Natera held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Natera by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $16M 172k 91.46

More positions owned by MPM Oncology Impact Management

Cullinan Oncology Common (CGEM)
Geron Corporation Common (GERN)
Iovance Biotherapeutics Common (IOVA)
Zentalis Pharmaceuticals Common (ZNTL)
iTeos Therapeutics Common (ITOS)
Sutro Biopharma Common (STRO)
Crinetics Pharmaceuticals Common (CRNX)
Olema Pharmaceuticals Common (OLMA)
Madrigal Pharmaceuticals Common (MDGL)
Natera Common (NTRA)
Werewolf Therapeutics Common (HOWL)
Moonlake Immunotherapeutics Class A Ord (MLTX)
Avadel Pharmaceuticals Sponsored ADR (AVDL)
Insmed Incorporated Common (INSM)
ALX Oncology Holdings Common (ALXO)

View all positions for MPM Oncology Impact Management

Top funds holding Natera

Vanguard Group
Jpmorgan Chase & Co
Fred Alger Management
BlackRock
Farallon Capital Management
Ameriprise Financial
Alliancebernstein
Millennium Management
Citadel Advisors
Massachusetts Financial Services
Kynam Capital Management
Samlyn Capital
Duquesne Family Office
Geode Capital Management
American Century Companies

View all funds holding Natera